Professor Profile: Benjamin M. Ellingson, Ph.D., M.S.
Professor
Office 924 Westwood Blvd, Suite 615
E-mail bellingson AT mednet DOT ucla DOT edu
Phone (310) 481-7572
Web Brain Tumor Imaging Labratory
Brain Tumor Imagain Labratory Courses
Research – Brain tumor imaging, metabolic imaging, clinical trials, therapeutics, schizophrenia, chronic pain, spinal cord injury, traumatic brain injury, epilepsy, neuroimaging, magnetic resonance imaging, PET imaging
Research Interest – Cancer Imaging and Neuroimaging
Background:
– Milwaukee School of Engineering, Milwaukee, WI BS 05/2003 Biomedical Engineering
– Marquette University, Milwaukee, WI MS 05/2005 Biomedical Engineering
– Medical College of Wisconsin & Marquette University, Milwaukee, WI PhD 05/2008 Functional Imaging Biomedical Engineering
– Medical College of Wisconsin, Milwaukee, WI Postdoctoral 06/2010 MRI
Favorite thing about UCLA? – Collaborative environment, passion for patient care and clinical innovation
Selected Publications – @National Library of Medicine
- Standardization of Radiographic Response Assessment for Drug Development in Neuro-Oncology
1. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. “Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials.” Neuro Oncology 2015 Sep; 17(9): 1188-98. PMID: 26250565. PMCID: PMC4588759.
2. Ellingson BM, Wen PY, Cloughesy TF. “Modified criteria for radiographic response assessment in glioblastoma clinical trials.” Neurotherapeutics 2017 Apr; 14(2): 307-320. PMID: 28108885. PMCID: PMC5398984.
3. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. “Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.” Neuro Oncol. 2016 Sep;18(9):1199-208. PMID: 27106405; PMCID: PMC4999003.
4. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. “Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.” Lancet Oncol. 2015 Nov;16(15):e534-e542. PMID: 26545842; PMCID: PMC4638131.
- Large-Scale Imaging Analyses Using Multiple Phase I-III Clinical Trials in Neuro-Oncology
1. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ*, Chakhoyan A*, Gahrmann R, Pope WB, Leu K*, Raymond C, Woodworth DC*, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. “Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.” Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. PMID: 28655794; PMCID: PMC5626594.
2. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. “Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Aug 2;20(9):1240-1250. PMID: 29660006; PMCID: PMC6071654.
3. Ellingson BM, Harris RJ*, Woodworth DC*, Leu K*, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. “Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.” Neuro Oncol. 2017 Jan;19(1):89-98. PMID: 27580889; PMCID: PMC5193027.
4. Ellingson BM, Kim HJ, Woodworth DC*, Pope WB, Cloughesy JN, Harris RJ*, Lai A, Nghiemphu PL, Cloughesy TF. “Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.” Radiology. 2014 Apr;271(1):200-10. PMID: 24475840; PMCID: PMC4263651.
- pH-Weighted Metabolic Imaging in Neuro-Oncology
1. Yao J*, Chakhoyan A*, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. “Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.” Neuro Oncol. 2019 May 4. pii: noz078. doi: 10.1093/ neuonc/ noz078. PMID: 31066901. PMCID In Process.
2. Harris RJ*, Yao J*, Chakhoyan A*, Raymond C, Leu K*, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. “Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).” Magn Reson Med. 2018 Nov;80(5):1962-1978. PMID: 29626359; PMCID: PMC6107417.
3. Harris RJ*, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM. “Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T.” NMR Biomed. 2016 Nov;29(11):1563-1576. PMID: 27717216. PMC In Process.
4. Harris RJ*, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. “pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.” Neuro Oncol. 2015 Nov;17(11):1514-24. PMID: 26113557; PMCID: PMC4648305.
- Molecular and Quantitative Imaging in Novel Therapeutics in Neuro-Oncology
1. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. “Neoadjuvant anti-PD immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.” Nat Med. 2019 Mar;25(3):477-486. PMID: 30742122; PMCID: PMC6408961.
2. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. “Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.” Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10220-10225. PMID: 28874539; PMCID: PMC5617282.
3. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. “Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.” Clin Cancer Res. 2014 Jul 1;20(13):3550-9. PMID: 24687922; PMCID: PMC4079729.
4. Harris RJ*, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. “18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.” Neuro Oncol. 2012 Aug;14(8):1079-89. PMID: 22711609; PMCID: PMC3408264.